FIG 2.

Patients with NET with CH had a lower platelet count at baseline. (A) Baseline blood counts. Patients with CH (VAF ≥2%) had lower platelet counts than those without CH (P = .03). There were no differences in HGB, MCV, WBC, ANC, or ALC. The horizontal line depicts median. (B) During four cycles of PRRT and at 3-month, 6-month and 12-month follow-ups, there was no significant difference in blood counts between groups. Mean with SD at each cycle and follow-up are shown. ALC, absolute lymphocyte count; ANC, absolute neutrophil count; CH, clonal hematopoiesis (defined by VAF ≥2%); Hgb, Hemoglobin; MCV, mean corpuscular volume; NET, neuroendocrine tumor; PLT, platelet; SD, standard deviation.